{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:34:17Z","timestamp":1771684457014,"version":"3.50.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,15]]},"DOI":"10.2169\/internalmedicine.9136-21","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T22:09:20Z","timestamp":1653948560000},"page":"2523-2526","source":"Crossref","is-referenced-by-count":19,"title":["Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma"],"prefix":"10.2169","volume":"61","author":[{"given":"Yayoi","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Okayama Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Okayama Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Okayama Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis 72: 1467-1474, 2021.","DOI":"10.1093\/cid\/ciaa1249"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tarhini H, Recoing A, Bridier-Nahmias A, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis 223: 1522-1527, 2021.","DOI":"10.1093\/infdis\/jiab075"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis 223: 23-27, 2021.","DOI":"10.1093\/infdis\/jiaa666"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dul\u00e9ry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol 96: 933-944, 2021.","DOI":"10.1002\/ajh.26209"},{"key":"5","unstructured":"5. Centers for Disease Control and Prevention. Ending isolation and precautions for people with COVID-19: interim guidance [Internet]. [cited 2022 Jan 14]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/duration-isolation.html"},{"key":"6","unstructured":"6. Buckland MS, Galloway JB, Fhogartaigh CN, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun 11: 6385, 2020."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Garibaldi BT, Wang K, Robinson ML, et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open 4: e213071, 2021.","DOI":"10.1001\/jamanetworkopen.2021.3071"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 8: CD014962, 2021.","DOI":"10.1002\/14651858.CD014962"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 25: 693-704, 2021.","DOI":"10.1056\/NEJMoa2021436"},{"key":"10","unstructured":"10. Pagano L, Salmanton-Garc\u00eda J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association survey (EPICOVIDEHA). J Hematol Oncol 14: 168, 2021."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Giesen N, Sprute R, R\u00fcthrich M, et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer 147: 154-160, 2021.","DOI":"10.1016\/j.ejca.2021.01.033"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Thakkar A, Pradhan K, Jindal S, et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer 2: 392-399, 2021.","DOI":"10.1038\/s43018-021-00191-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother 27: 387-389, 2021.","DOI":"10.1016\/j.jiac.2020.12.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma 57: 512-519, 2016.","DOI":"10.3109\/10428194.2015.1110748"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Regalado-Artamendi I, Jim\u00e9nez-Ubieto A, Hern\u00e1ndez-Rivas J\u00c1, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere 5: e538, 2021.","DOI":"10.1097\/HS9.0000000000000538"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_9136-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T03:18:30Z","timestamp":1660965510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_9136-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":15,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9136-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"9136-21"}}